Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Serologic assays are an essential tool for seroprevalence surveys, for quality control of vaccines, and to determine the response to vaccination. Although a correlate of immunity has not yet been established for COVID-19 vaccines, antibody titers after natural infection and vaccination have been associated with protection from symptomatic SARS-CoV-2 infection.
Article activity feed
-
-
SciScore for 10.1101/2021.12.17.21267927: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding Evaluators were blinded as to the origin of the samples. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 Rapid Antibody Test: The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM and IgG antibodies, and the intensity of the test line is dependent upon the level of SARS-CoV-2 antibodies present in the sample (26). IgGsuggested: NoneSARS-CoV-2suggested: NoneElecsys Anti-SARS-CoV-2 S assay: The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as negative … SciScore for 10.1101/2021.12.17.21267927: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding Evaluators were blinded as to the origin of the samples. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 Rapid Antibody Test: The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM and IgG antibodies, and the intensity of the test line is dependent upon the level of SARS-CoV-2 antibodies present in the sample (26). IgGsuggested: NoneSARS-CoV-2suggested: NoneElecsys Anti-SARS-CoV-2 S assay: The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as negative and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies (23). anti-SARS-CoV-2 Ssuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The findings of this study are subject to several limitations. The performance of the SARS-CoV-2 Rapid Antibody Test in vaccinated individuals was based on the evaluation of a relatively small panel of samples and utilized only two vaccines. However, the cohort tested was generally representative of an aged US population, with hypertension and diabetes mellitus in line with age-related expectations of prevalence (41, 42). The clinical relevance of semi-quantitative results is currently unknown and, at present, cannot be interpreted as an indication of varying levels of immunity. However, semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S assay results correlated well, suggesting that SARS-CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) into the vaccinated population.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
